Drug firm Sharon Bio Medicine today said it has received approval from the European health regulator to market its product Trimetazidine Dihydrochloride used for treating angina and vertigo in the European market.
"The company has received Certificate of Suitability for trimetazidine dihydrochloride from European Directorate for quality of Medicines and Healthcare (EDQM)," Sharon Bio Medicine said in a filing to the Bombay Stock Exchange.
The certificate has been given after the evaluation of the drug master file (DMF) and is valid for five years. The certificate is renewable, the company added.
This approval will allow the company to supply the medicine to Europe and give better sales and margins in the future, Sharon Bio Medicine said.
The product is manufactured at the firms plant at Taloja near Navi Mumbai, it added.
Shares of Sharon Bio Medicine were today trading at Rs 168 in the after noon trade on BSE, up 0.36% from its previous close.